Oncodesign Precision Medicine (XPAR:ALOPM) Institutional Ownership: 0.79% (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALOPM Oncodesign Precision Medicine SA XPAR:ALOPM
38 GF Score
Price €0.32
GF Value €0.29
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Institutional Ownership?

Oncodesign Precision Medicine XPAR:ALOPM +0.31% 38 Institutional Ownership is 0.79% as of Aug. 10, 2026. GuruFocus rates XPAR:ALOPM with a GF Score™ of 38/100 and a GF Value™ of €0.29 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Oncodesign Precision Medicine's institutional ownership is 0.79%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Oncodesign Precision Medicine's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Oncodesign Precision Medicine's Float Percentage Of Total Shares Outstanding is 0.00%.

Oncodesign Precision Medicine Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Oncodesign Precision Medicine's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Institutional Ownership Chart

Oncodesign Precision Medicine Historical Data

The historical data trend for Oncodesign Precision Medicine can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 0.87 0.87 0.87 0.86 0.86 0.83 0.83 0.83 0.79 0.79
XPAR:ALOPM
38GF Score
Oncodesign Precision Medicine SA XPAR:ALOPM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncodesign Precision Medicine Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.79% mean?
Oncodesign Precision Medicine (XPAR:ALOPM) has a Institutional Ownership of 0.79% as of Aug. 10, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Oncodesign Precision Medicine and its competitors.
Is Oncodesign Precision Medicine's Institutional Ownership too high?
Oncodesign Precision Medicine's current Institutional Ownership is 0.79%. Overall, Oncodesign Precision Medicine has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncodesign Precision Medicine's Institutional Ownership compare to VRTX and REGN?
Oncodesign Precision Medicine's Institutional Ownership of 0.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Oncodesign Precision Medicine and its competitors. Oncodesign Precision Medicine's current Institutional Ownership is 0.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncodesign Precision Medicine stock overvalued right now?
Based on GuruFocus' analysis, Oncodesign Precision Medicine (XPAR:ALOPM) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.29, compared to a current price of €0.32 — trading 11% above its estimated fair value. The current Institutional Ownership is 0.79%. Oncodesign Precision Medicine's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Oncodesign Precision Medicine (XPAR:ALOPM), the current Institutional Ownership is 0.79% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncodesign Precision Medicine (XPAR:ALOPM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.32 is trading 11% above its estimated GF Value™ of €0.29. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for XPAR:ALOPM:

  • Institutional Ownership: 0.79%
  • GF Value™: €0.29 vs. price of €0.32 (11% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the XPAR:ALOPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncodesign Precision Medicine Business Description

Other Exchanges ZR8:Germany
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
38GF Score

Get the complete analysis for XPAR:ALOPM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price
€0.29
GF Value